| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d94bf812f0adb56a9d550ae285ff489
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25e70f1d04d1fdffca0a301d73478008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbdce5f746cc8d0eb6681612a64c6935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_319d761a9372b42a26bf24c9a69a589b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2001-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f12ac131e26574306f4f7a71acafbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_002a102a2c39dfffd526c590040a09e8 |
| publicationDate |
2001-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0162799-A2 |
| titleOfInvention |
Method for inhibiting angiogenesis using molecules that enhance plasmin activity |
| abstract |
The invention provides a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation for use as a pharmaceutical. The invention further provides use of a proteinaceous molecule according to the invention for the preparation of a medicament for the treatment of diseases related with angiogenesis and/or inflammatory disorders and/or conformational disorders and/or ageing. Furthermore the invention provides a proteinaceous molecule to suppress tumor growth, to regress established tumors, to degrade amyloid-β and to inhibit amyloid-β action. Additionally the invention provides a method for the treatment of a disease associated with or dependent on angiogenesis and/or associated with amyloid deposition comprising administering to a patient an effective amount of a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8114832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021190558-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021190562-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8158585-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8067187-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7887800-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7479270-B2 |
| priorityDate |
2000-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |